Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| CELG | Celgene Corporation | 0.55% | 89.14 | 1.3% | $797.85m | |
| AMGN | Amgen Inc. | 1.08% | 187.50 | 1.2% | $644.97m | |
| GILD | Gilead Sciences, Inc. | 0.29% | 65.74 | 0.9% | $476.37m | |
| BIIB | Biogen Inc. | 1.30% | 325.33 | 1.3% | $432.61m | |
| ILMN | Illumina, Inc. | 1.41% | 301.06 | 3.5% | $311.78m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 0.93% | 422.52 | 2.6% | $280.54m | |
| VRTX | Vertex Pharmaceuticals Incorporated | 1.48% | 185.76 | 1.9% | $246.69m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 1.71% | 129.73 | 2.0% | $214.36m | |
| SRPT | Sarepta Therapeutics, Inc. | 2.52% | 139.98 | 15.4% | $157.00m | |
| A | Agilent Technologies, Inc. | 0.67% | 78.41 | 1.6% | $155.05m | |
| EXAS | Exact Sciences Corporation | 10.52% | 92.04 | 25.3% | $150.72m | |
| INCY | Incyte Corporation | 1.82% | 84.85 | 2.5% | $112.02m | |
| ARRY | Array BioPharma Inc. | 2.33% | 23.24 | 8.2% | $111.41m | |
| NBIX | Neurocrine Biosciences, Inc. | 2.07% | 78.91 | 5.1% | $80.47m | |
| EXEL | Exelixis, Inc. | 1.41% | 21.52 | 6.4% | $79.74m |
Company Profile
Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Its efforts are currently focused primarily on the development of vosaroxin for the treatment of acute myeloid leukemia. The firms activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA.